Plerixafor
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Plerixafor |
| DrugBank ID | DB06809 |
| Brand Names (EU) | Plerixafor Accord |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Adult patients Plerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2). Paediatric patients (1 to less than 18 years) Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | plasma cell myeloma | 99.98% | DL |
| 2 | indolent plasma cell myeloma | 99.97% | DL |
| 3 | CMM7 | 99.34% | DL |
| 4 | pediatric leptomeningeal melanoma | 99.30% | DL |
| 5 | epithelioid cell uveal melanoma | 99.27% | DL |
| 6 | bronchitis | 99.22% | DL |
| 7 | vulvar melanoma (disease) | 99.17% | DL |
| 8 | myeloid leukemia | 99.02% | DL |
| 9 | melanoma | 98.96% | DL |
| 10 | cecum villous adenoma | 98.92% | DL |
| 11 | cecum neuroendocrine tumor G1 | 98.89% | DL |
| 12 | rectosigmoid junction neoplasm | 98.88% | DL |
| 13 | colonic neoplasm | 98.88% | DL |
| 14 | lipoma of colon | 98.88% | DL |
| 15 | cecal disease | 98.87% | DL |
| 16 | colon leiomyoma | 98.86% | DL |
| 17 | benign neoplasm of cecum | 98.84% | DL |
| 18 | colonic lymphangioma | 98.83% | DL |
| 19 | cavernous hemangioma of colon | 98.61% | DL |
| 20 | intellectual disability, autosomal dominant 55, with seizures | 97.84% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.